Ranbaxy Likely To Go Solo For Lipitor Launch; FDA Closer To Resolving Manufacturing Issues
This article was originally published in PharmAsia News
You may also be interested in...
Countdown To Generic Lipitor: Watson Expects Pfizer To Retain 40% Market Share For Six Months
Watson, which will launch an authorized generic Nov. 30, says Pfizer is trying to get pharmacy benefit managers to give Lipitor preferred formulary status.
Zyprexa Goes Generic: Teva Fills "Basket" Of Doses With Dr. Reddy's Deal
Teva Pharmaceutical Industries greeted the patent expiration of Lilly’s Zyprexa (olanzapine) by launching all six tablet doses of the antipsychotic, thanks to an agreement with Dr. Reddy’s Laboratories Ltd.
Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty
MUMBAI - Share prices of Ranbaxy Laboratories Ltd. rose nearly 5% on an otherwise flat day of trading at the Bombay Stock Exchange backed by news that the company is "on schedule" to launch generic versions of Lipitor (atorvastatin) in the United States